Gibson, C. M. Et Al. 2017. Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). CIRCULATION , vol.135, no.7 , 648-655.

Gibson, C. M., Chi, G., Halaby, R., Korjian, S., Daaboul, Y., Jain, P., ... Arbetter, D.(2017). Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). CIRCULATION , vol.135, no.7, 648-655.

Gibson, C. Et Al. "Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban)," CIRCULATION , vol.135, no.7, 648-655, 2017

Gibson, C. M. Et Al. "Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban)." CIRCULATION , vol.135, no.7, pp.648-655, 2017

Gibson, C. M. Et Al. (2017) . "Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban)." CIRCULATION , vol.135, no.7, pp.648-655.

@article{article, author={C. Michael Gibson Et Al. }, title={Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban)}, journal={CIRCULATION}, year=2017, pages={648-655} }